Viral replication dynamics could critically modulate vaccine effectiveness and should be accounted for when assessing new SARS-CoV-2 variants.
作者信息
Yang Wan, Shaman Jeffrey
机构信息
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.
Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, New York, USA.
出版信息
Influenza Other Respir Viruses. 2022 Mar;16(2):366-367. doi: 10.1111/irv.12961. Epub 2022 Jan 10.
Abstract
摘要
相似文献
1
Viral replication dynamics could critically modulate vaccine effectiveness and should be accounted for when assessing new SARS-CoV-2 variants.病毒复制动态可能会严重影响疫苗效力，在评估新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体时应予以考虑。
Influenza Other Respir Viruses. 2022 Mar;16(2):366-367. doi: 10.1111/irv.12961. Epub 2022 Jan 10.
2
COVID-19 vaccine breakthrough infections.COVID-19 疫苗突破性感染。
Science. 2021 Dec 24;374(6575):1561-1562. doi: 10.1126/science.abl8487. Epub 2021 Dec 23.
3
Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.mRNA-1273 疫苗加强针可预防非人类灵长类动物感染 SARS-CoV-2 Beta 变体。
Science. 2021 Dec 10;374(6573):1343-1353. doi: 10.1126/science.abl8912. Epub 2021 Oct 21.
4
Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern.预测的表位丰度支持针对 SARS-CoV-2 关切变异株的疫苗诱导的细胞毒性保护。
Front Immunol. 2021 Nov 25;12:732693. doi: 10.3389/fimmu.2021.732693. eCollection 2021.
5
Assessing the human immune response to SARS-CoV-2 variants.评估人类对新冠病毒变异株的免疫反应。
Nat Med. 2021 Apr;27(4):571-572. doi: 10.1038/s41591-021-01290-0.
6
Effectiveness of Coronavirus Vaccines against Syndrome Coronavirus 2 (SARS-CoV-2) and Its New Variants.冠状病毒疫苗对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）及其变体的有效性。
Iran J Allergy Asthma Immunol. 2021 Dec 8;20(6):647-671. doi: 10.18502/ijaai.v20i6.8016.
7
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.第三次BNT162b2疫苗接种对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎感染的中和作用
N Engl J Med. 2022 Feb 3;386(5):492-494. doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.
8
Audio Interview: Waning Immunity against SARS-CoV-2.音频访谈：针对严重急性呼吸综合征冠状病毒2的免疫力下降
N Engl J Med. 2021 Dec 9;385(24):e99. doi: 10.1056/NEJMe2119211.
9
Audio Interview: Another New Covid-19 Vaccine.音频访谈：又一种新型新冠疫苗
N Engl J Med. 2021 Jul 1;385(1):e13. doi: 10.1056/NEJMe2110939.
10
A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.一种表达融合前稳定的 SARS-CoV-2 刺突蛋白的 MVA 疫苗单次接种即可中和关注变体，并保护小鼠免受致死性 SARS-CoV-2 感染。
Front Immunol. 2022 Jan 27;12:824728. doi: 10.3389/fimmu.2021.824728. eCollection 2021.
引用本文的文献
1
Host and viral determinants of airborne transmission of SARS-CoV-2 in the Syrian hamster.宿主和病毒因素决定 SARS-CoV-2 在叙利亚仓鼠中的空气传播。
Elife. 2024 Feb 28;12:RP87094. doi: 10.7554/eLife.87094.
2
Prevention of respiratory virus transmission by resident memory CD8 T cells.通过驻留记忆 CD8 T 细胞预防呼吸道病毒传播。
Nature. 2024 Feb;626(7998):392-400. doi: 10.1038/s41586-023-06937-1. Epub 2023 Dec 12.
3
Host and viral determinants of airborne transmission of SARS-CoV-2 in the Syrian hamster.叙利亚仓鼠中SARS-CoV-2空气传播的宿主和病毒决定因素。
bioRxiv. 2023 Oct 9:2022.08.15.504010. doi: 10.1101/2022.08.15.504010.
本文引用的文献
1
Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant.新冠病毒德尔塔变异株引发的大型溯源清晰的暴发中的病毒感染和传播。
Nat Commun. 2022 Jan 24;13(1):460. doi: 10.1038/s41467-022-28089-y.
2
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.BNT162b2 mRNA COVID-19 疫苗加强针在预防以色列重症结局的有效性：一项观察性研究。
Lancet. 2021 Dec 4;398(10316):2093-2100. doi: 10.1016/S0140-6736(21)02249-2. Epub 2021 Oct 29.
3
Waning Immunity after the BNT162b2 Vaccine in Israel.以色列接种 BNT162b2 疫苗后的免疫力下降。
N Engl J Med. 2021 Dec 9;385(24):e85. doi: 10.1056/NEJMoa2114228. Epub 2021 Oct 27.
4
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.辉瑞-BioNTech 信使核糖核酸 COVID-19 疫苗在美国大型综合卫生系统中的 6 个月有效性：一项回顾性队列研究。
Lancet. 2021 Oct 16;398(10309):1407-1416. doi: 10.1016/S0140-6736(21)02183-8. Epub 2021 Oct 4.
5
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.卡塔尔：BNT162b2 疫苗对 SARS-CoV-2 感染的保护作用逐渐减弱。
N Engl J Med. 2021 Dec 9;385(24):e83. doi: 10.1056/NEJMoa2114114. Epub 2021 Oct 6.
6
The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients.在新诊断的新冠患者的鼻咽样本中，新冠病毒德尔塔变异株的病毒载量高于贝塔变异株和既往变异株。
J Infect. 2021 Oct;83(4):e1-e3. doi: 10.1016/j.jinf.2021.08.027. Epub 2021 Aug 19.
7
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.BNT162b2疫苗对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株B.1.617.2和B.1.351的中和抗体活性
Lancet. 2021 Jun 19;397(10292):2331-2333. doi: 10.1016/S0140-6736(21)01290-3. Epub 2021 Jun 3.
8
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.多种 SARS-CoV-2 变异株逃避疫苗诱导的体液免疫中和作用。
Cell. 2021 Apr 29;184(9):2372-2383.e9. doi: 10.1016/j.cell.2021.03.013. Epub 2021 Mar 12.
Zotero 插件